SLC5A2 and kidney disorder: From a pharmacoeconomics perspective, if the efficacy and safety results of EMPA-REG OUTCOME, CANVAS, and LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) were confirmed by real-world evidence, treatment with SGLT-2 inhibitors would become a more cost-effective strategy to achieve glycemic control and prevent cardiovascular death and nephropathy in T2DM patients [17], with the advantage of oral administration.